stockportfolio.pro
Stocks / IDXX vs TEVA
IDXX vs TEVA
IDEXX Laboratories, Inc. and Teva Pharmaceutical Industries Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| IDEXX Laboratories, Inc. (IDXX) | Teva Pharmaceutical Industries Limited (TEVA) | |
|---|---|---|
| Market cap | $45.0B | $40.1B |
| Revenue (latest FY) | $4.30B | $17.26B |
| Net income (latest FY) | $1.06B | $1.41B |
| Revenue growth (5y CAGR) | 9.7% | 0.7% |
| Net margin | 24.6% | 8.2% |
| Return on equity | 66.0% | 17.8% |
| P/E ratio | 42.0 | 25.7 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 3 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open IDXX — free Open TEVA — freeFrequently asked questions
Which is bigger, IDXX or TEVA?
IDEXX Laboratories, Inc. is larger by market capitalization — $45.0B versus $40.1B.
Which grows faster, IDXX or TEVA?
Over the last five fiscal years, IDEXX Laboratories, Inc. grew revenue faster — 9.7%/yr versus 0.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.